Complementary Medicine in Multiple Sclerosis

Phase 3

• Conditions: Multiple Sclerosis.; Multiple sclerosis

• Registration Number: IRCT20181113041641N2
• Lead Sponsor: Artesh University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Secondary-Progressive MS patients (diagnosed by a neurologist according to expanded disability status scale)
Aged between 18-60 years old.
Receiving vitamin D3 50000 IU orally per week
Consent to participate in the study

Exclusion Criteria

Concurrent participation in other clinical trials
COVID-19 infection
Type 2 diabetes
Regular intake of anti-anxiety and anti-depressant drugs
The occurrence of MS attack
Smoking (at least two cigarettes per day)
Adherence to special diets or nutritional supplements

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum level of high sensitivity C-Reactive Protein (hs-CRP). Timepoint: At baseline and 8 weeks later. Method of measurement: Chemi Luminescent ImmunoAssays (CLIAs).;Serum Estimated Sedimentation Rate (ESR). Timepoint: At baseline and 8 weeks later. Method of measurement: Westergren method.;Quality of life. Timepoint: At baseline and 8 weeks later. Method of measurement: Multiple Sclerosis Quality of Life (MSQOL-54) 54 items.;Disease activity. Timepoint: At baseline and 8 weeks later. Method of measurement: scoring form of Expanded Disability Status Scale (EDSS).